# CP-CTNet Coordinating Center

> **NIH NIH U24** · UNIVERSITY OF WISCONSIN-MADISON · 2021 · $2,539,929

## Abstract

Project Summary/Abstract
Cancer is the leading cause of morbidity and mortality in the US and in the world. One approach to reducing
the risk and burden of cancer is to use preventive agents and interventions that are effective and safe.
According to the Division of Cancer Prevention (DCP) at the National Cancer Institute (NCI), this requires the
systematic development of cancer preventive agents and interventions, with three critical components; i)
preclinical/toxicology studies for identification of agents, ii) early phase trials of identified agents and other
promising interventions, and iii) late phase III trials of preventive agents and interventions that have
successfully passed through early phase trials, in a three-legged approach.
The goal of the Cancer Prevention Clinical Trials Network (CP-CTNet) is to identify safe and effective
preventive agents and interventions in order to advance their further clinical development for cancer
prevention. Further clinical development is to be undertaken in late phase III trials conducted by the third leg,
i.e. the National Community Oncology Research Program (NCORP), supported by the DCP's Community
Oncology and Prevention Trials Research Group, to ultimately reduce the risk and burden of cancer. As the
second leg of this three-legged approach, the CP-CTNet will conduct early phase trials to assess the safety,
tolerability, and cancer preventive potential of agents and interventions of varying classes identified by the first
leg, i.e. the DCP's Cancer Preclinical Drug Development Program (PREVENT) support of preclinical/toxicology
studies, many of which target molecules or processes known to be important during carcinogenesis. The CP-
CTNet Sites will perform these early phase trials supported by the DCP and the CP-CTNet Data Management,
Auditing, and Coordinating Center (DMACC). These trials include phase 0 (micro-dosing), phase I (dose-
finding), and phase II (preliminary efficacy) clinical trials.
To support these early phase trials, which will be conducted by the CP-CTNet sites alone or as cross-Network
trials, the CP-CTNet DMACC will coordinate trans-Network activities and provide expertise and resources in 1)
centralized data management and reporting, 2) clinical trials auditing, and 3) administrative and logistical
coordination, including expertise in clinical trials methodology and biostatistics, across CP-CTNet. In addition,
the CP-CTNet DMACC will provide an advisory role in early phase caner prevention trial development for all
CP-CTNet trials and the primary statistical role for cross-Network trials.

## Key facts

- **NIH application ID:** 10245102
- **Project number:** 5U24CA242637-03
- **Recipient organization:** UNIVERSITY OF WISCONSIN-MADISON
- **Principal Investigator:** KyungMann Kim
- **Activity code:** U24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $2,539,929
- **Award type:** 5
- **Project period:** 2019-09-20 → 2024-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10245102

## Citation

> US National Institutes of Health, RePORTER application 10245102, CP-CTNet Coordinating Center (5U24CA242637-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10245102. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*